Geographical clustering of cases of infection with moxifloxacin-resistant Clostridium difficile PCR-ribotypes 012, 017 and 046 in Sweden, 2008 and 2009

We report the results of two nationwide surveillance studies of Clostridium difficile infection conducted during 2008 and 2009 in Sweden. The first study aimed to identify and quantify the proportion of C. difficile isolates with decreased susceptibility to moxifloxacin, particularly those of PCR-ri...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Euro surveillance : bulletin européen sur les maladies transmissibles 2011-03, Vol.16 (10), p.18
Hauptverfasser: Akerlund, T, Alefjord, I, Dohnhammar, U, Struwe, J, Noren, T, Tegmark-Wisell, K
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 10
container_start_page 18
container_title Euro surveillance : bulletin européen sur les maladies transmissibles
container_volume 16
creator Akerlund, T
Alefjord, I
Dohnhammar, U
Struwe, J
Noren, T
Tegmark-Wisell, K
description We report the results of two nationwide surveillance studies of Clostridium difficile infection conducted during 2008 and 2009 in Sweden. The first study aimed to identify and quantify the proportion of C. difficile isolates with decreased susceptibility to moxifloxacin, particularly those of PCR-ribotype 027. From December 2007 to September 2008, 20 of 28 regional laboratories sent 585 isolates to the Swedish Institute for Infectious Disease Control for typing. A majority of the isolates (454 of 585; 78%) belonged to four PCR ribotypes (012, SE37, 017 and 046), all clustered in geographical regions. Only two type 027 isolates were found, both from the same patient. In the second study, involving all 28 regional laboratories, all consecutive C. difficile isolates collected during two time periods in 2009 (n=364) were typed and tested for susceptibility to clindamycin, erythromycin, moxifloxacin, metronidazole and vancomycin. The three most common PCR ribotypes were SE21, 001 and 020 (22% of all isolates). Types 012, 017, and 046 were geographically clustered and associated with decreased susceptibility to moxifloxacin, clindamycin and erythromcin. The extent of moxifloxacin prescription was highly variable among counties, indicating a need for careful monitoring of prescription rates to follow its role in C. difficile epidemiology.
doi_str_mv 10.2807/ese.16.10.19813-en
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_865693630</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>865693630</sourcerecordid><originalsourceid>FETCH-LOGICAL-c373t-858b5b85957c847009c3481e22c884190c2950e0ac3c7e4cc251ca0e7bf933713</originalsourceid><addsrcrecordid>eNpdUU1v1TAQtBCIlsIf4IAsLlyaV3_EsX1ET7QgVQIVOFvOZtO6SuyHnajtL-Hv1q8tCHHZnV3NzK40hLzlbCMM0ydYcMO7TR25NVw2GJ-RQ6461mjL9fN_8AF5Vco1Y61kVrwkB4K3UkkhDsnvM0yX2e-uAviJwrSWBXOIlzSNFHzBsgchjghLSJHehOWKzuk2jFO69RBik7GEsvi40O2UypLDENaZDmEcA4QJ6bftRZNDn5a7XTVjXBzXoqmPA2VtV63p9xscMB5TwZh52FdgX5MXo58KvnnqR-Tn6acf28_N-dezL9uP5w1ILZfGKNOr3iirNJhWVyHI1nAUAoxpuWUgrGLIPEjQ2AIIxcEz1P1opdRcHpEPj767nH6tWBY3hwI4TT5iWoszneqs7CSrzPf_Ma_TmmN9zhml6zGh9iTxSIKcSsk4ul0Os893jjO3D83V0Bzv9uNDaA5jFb17cl77GYe_kj8pyXsNSZFD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>857841250</pqid></control><display><type>article</type><title>Geographical clustering of cases of infection with moxifloxacin-resistant Clostridium difficile PCR-ribotypes 012, 017 and 046 in Sweden, 2008 and 2009</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Akerlund, T ; Alefjord, I ; Dohnhammar, U ; Struwe, J ; Noren, T ; Tegmark-Wisell, K</creator><creatorcontrib>Akerlund, T ; Alefjord, I ; Dohnhammar, U ; Struwe, J ; Noren, T ; Tegmark-Wisell, K ; Swedish C. difficile Study Group</creatorcontrib><description>We report the results of two nationwide surveillance studies of Clostridium difficile infection conducted during 2008 and 2009 in Sweden. The first study aimed to identify and quantify the proportion of C. difficile isolates with decreased susceptibility to moxifloxacin, particularly those of PCR-ribotype 027. From December 2007 to September 2008, 20 of 28 regional laboratories sent 585 isolates to the Swedish Institute for Infectious Disease Control for typing. A majority of the isolates (454 of 585; 78%) belonged to four PCR ribotypes (012, SE37, 017 and 046), all clustered in geographical regions. Only two type 027 isolates were found, both from the same patient. In the second study, involving all 28 regional laboratories, all consecutive C. difficile isolates collected during two time periods in 2009 (n=364) were typed and tested for susceptibility to clindamycin, erythromycin, moxifloxacin, metronidazole and vancomycin. The three most common PCR ribotypes were SE21, 001 and 020 (22% of all isolates). Types 012, 017, and 046 were geographically clustered and associated with decreased susceptibility to moxifloxacin, clindamycin and erythromcin. The extent of moxifloxacin prescription was highly variable among counties, indicating a need for careful monitoring of prescription rates to follow its role in C. difficile epidemiology.</description><identifier>ISSN: 1560-7917</identifier><identifier>ISSN: 1025-496X</identifier><identifier>EISSN: 1560-7917</identifier><identifier>DOI: 10.2807/ese.16.10.19813-en</identifier><identifier>PMID: 21435322</identifier><language>eng</language><publisher>Sweden: Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)</publisher><subject>Anti-Bacterial Agents - pharmacology ; Aza Compounds - pharmacology ; Bacteria ; Clostridium difficile - classification ; Clostridium difficile - drug effects ; Clostridium difficile - genetics ; Clostridium difficile - isolation &amp; purification ; Cluster Analysis ; DNA Gyrase - genetics ; Drug resistance ; Drug Resistance, Bacterial ; Enterocolitis, Pseudomembranous - epidemiology ; Enterocolitis, Pseudomembranous - microbiology ; Epidemiology ; Fluoroquinolones ; Geography ; Humans ; Infectious diseases ; Laboratories ; Microbial Sensitivity Tests ; Molecular Epidemiology ; Moxifloxacin ; Polymerase Chain Reaction ; Population Surveillance ; Prescription drugs ; Prevalence ; Quinolines - pharmacology ; Ribotyping ; Surveillance ; Sweden - epidemiology</subject><ispartof>Euro surveillance : bulletin européen sur les maladies transmissibles, 2011-03, Vol.16 (10), p.18</ispartof><rights>Copyright Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS) Mar 10, 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c373t-858b5b85957c847009c3481e22c884190c2950e0ac3c7e4cc251ca0e7bf933713</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21435322$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Akerlund, T</creatorcontrib><creatorcontrib>Alefjord, I</creatorcontrib><creatorcontrib>Dohnhammar, U</creatorcontrib><creatorcontrib>Struwe, J</creatorcontrib><creatorcontrib>Noren, T</creatorcontrib><creatorcontrib>Tegmark-Wisell, K</creatorcontrib><creatorcontrib>Swedish C. difficile Study Group</creatorcontrib><title>Geographical clustering of cases of infection with moxifloxacin-resistant Clostridium difficile PCR-ribotypes 012, 017 and 046 in Sweden, 2008 and 2009</title><title>Euro surveillance : bulletin européen sur les maladies transmissibles</title><addtitle>Euro Surveill</addtitle><description>We report the results of two nationwide surveillance studies of Clostridium difficile infection conducted during 2008 and 2009 in Sweden. The first study aimed to identify and quantify the proportion of C. difficile isolates with decreased susceptibility to moxifloxacin, particularly those of PCR-ribotype 027. From December 2007 to September 2008, 20 of 28 regional laboratories sent 585 isolates to the Swedish Institute for Infectious Disease Control for typing. A majority of the isolates (454 of 585; 78%) belonged to four PCR ribotypes (012, SE37, 017 and 046), all clustered in geographical regions. Only two type 027 isolates were found, both from the same patient. In the second study, involving all 28 regional laboratories, all consecutive C. difficile isolates collected during two time periods in 2009 (n=364) were typed and tested for susceptibility to clindamycin, erythromycin, moxifloxacin, metronidazole and vancomycin. The three most common PCR ribotypes were SE21, 001 and 020 (22% of all isolates). Types 012, 017, and 046 were geographically clustered and associated with decreased susceptibility to moxifloxacin, clindamycin and erythromcin. The extent of moxifloxacin prescription was highly variable among counties, indicating a need for careful monitoring of prescription rates to follow its role in C. difficile epidemiology.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Aza Compounds - pharmacology</subject><subject>Bacteria</subject><subject>Clostridium difficile - classification</subject><subject>Clostridium difficile - drug effects</subject><subject>Clostridium difficile - genetics</subject><subject>Clostridium difficile - isolation &amp; purification</subject><subject>Cluster Analysis</subject><subject>DNA Gyrase - genetics</subject><subject>Drug resistance</subject><subject>Drug Resistance, Bacterial</subject><subject>Enterocolitis, Pseudomembranous - epidemiology</subject><subject>Enterocolitis, Pseudomembranous - microbiology</subject><subject>Epidemiology</subject><subject>Fluoroquinolones</subject><subject>Geography</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Laboratories</subject><subject>Microbial Sensitivity Tests</subject><subject>Molecular Epidemiology</subject><subject>Moxifloxacin</subject><subject>Polymerase Chain Reaction</subject><subject>Population Surveillance</subject><subject>Prescription drugs</subject><subject>Prevalence</subject><subject>Quinolines - pharmacology</subject><subject>Ribotyping</subject><subject>Surveillance</subject><subject>Sweden - epidemiology</subject><issn>1560-7917</issn><issn>1025-496X</issn><issn>1560-7917</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUU1v1TAQtBCIlsIf4IAsLlyaV3_EsX1ET7QgVQIVOFvOZtO6SuyHnajtL-Hv1q8tCHHZnV3NzK40hLzlbCMM0ydYcMO7TR25NVw2GJ-RQ6461mjL9fN_8AF5Vco1Y61kVrwkB4K3UkkhDsnvM0yX2e-uAviJwrSWBXOIlzSNFHzBsgchjghLSJHehOWKzuk2jFO69RBik7GEsvi40O2UypLDENaZDmEcA4QJ6bftRZNDn5a7XTVjXBzXoqmPA2VtV63p9xscMB5TwZh52FdgX5MXo58KvnnqR-Tn6acf28_N-dezL9uP5w1ILZfGKNOr3iirNJhWVyHI1nAUAoxpuWUgrGLIPEjQ2AIIxcEz1P1opdRcHpEPj767nH6tWBY3hwI4TT5iWoszneqs7CSrzPf_Ma_TmmN9zhml6zGh9iTxSIKcSsk4ul0Os893jjO3D83V0Bzv9uNDaA5jFb17cl77GYe_kj8pyXsNSZFD</recordid><startdate>20110310</startdate><enddate>20110310</enddate><creator>Akerlund, T</creator><creator>Alefjord, I</creator><creator>Dohnhammar, U</creator><creator>Struwe, J</creator><creator>Noren, T</creator><creator>Tegmark-Wisell, K</creator><general>Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110310</creationdate><title>Geographical clustering of cases of infection with moxifloxacin-resistant Clostridium difficile PCR-ribotypes 012, 017 and 046 in Sweden, 2008 and 2009</title><author>Akerlund, T ; Alefjord, I ; Dohnhammar, U ; Struwe, J ; Noren, T ; Tegmark-Wisell, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c373t-858b5b85957c847009c3481e22c884190c2950e0ac3c7e4cc251ca0e7bf933713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Aza Compounds - pharmacology</topic><topic>Bacteria</topic><topic>Clostridium difficile - classification</topic><topic>Clostridium difficile - drug effects</topic><topic>Clostridium difficile - genetics</topic><topic>Clostridium difficile - isolation &amp; purification</topic><topic>Cluster Analysis</topic><topic>DNA Gyrase - genetics</topic><topic>Drug resistance</topic><topic>Drug Resistance, Bacterial</topic><topic>Enterocolitis, Pseudomembranous - epidemiology</topic><topic>Enterocolitis, Pseudomembranous - microbiology</topic><topic>Epidemiology</topic><topic>Fluoroquinolones</topic><topic>Geography</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Laboratories</topic><topic>Microbial Sensitivity Tests</topic><topic>Molecular Epidemiology</topic><topic>Moxifloxacin</topic><topic>Polymerase Chain Reaction</topic><topic>Population Surveillance</topic><topic>Prescription drugs</topic><topic>Prevalence</topic><topic>Quinolines - pharmacology</topic><topic>Ribotyping</topic><topic>Surveillance</topic><topic>Sweden - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akerlund, T</creatorcontrib><creatorcontrib>Alefjord, I</creatorcontrib><creatorcontrib>Dohnhammar, U</creatorcontrib><creatorcontrib>Struwe, J</creatorcontrib><creatorcontrib>Noren, T</creatorcontrib><creatorcontrib>Tegmark-Wisell, K</creatorcontrib><creatorcontrib>Swedish C. difficile Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Euro surveillance : bulletin européen sur les maladies transmissibles</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akerlund, T</au><au>Alefjord, I</au><au>Dohnhammar, U</au><au>Struwe, J</au><au>Noren, T</au><au>Tegmark-Wisell, K</au><aucorp>Swedish C. difficile Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Geographical clustering of cases of infection with moxifloxacin-resistant Clostridium difficile PCR-ribotypes 012, 017 and 046 in Sweden, 2008 and 2009</atitle><jtitle>Euro surveillance : bulletin européen sur les maladies transmissibles</jtitle><addtitle>Euro Surveill</addtitle><date>2011-03-10</date><risdate>2011</risdate><volume>16</volume><issue>10</issue><spage>18</spage><pages>18-</pages><issn>1560-7917</issn><issn>1025-496X</issn><eissn>1560-7917</eissn><abstract>We report the results of two nationwide surveillance studies of Clostridium difficile infection conducted during 2008 and 2009 in Sweden. The first study aimed to identify and quantify the proportion of C. difficile isolates with decreased susceptibility to moxifloxacin, particularly those of PCR-ribotype 027. From December 2007 to September 2008, 20 of 28 regional laboratories sent 585 isolates to the Swedish Institute for Infectious Disease Control for typing. A majority of the isolates (454 of 585; 78%) belonged to four PCR ribotypes (012, SE37, 017 and 046), all clustered in geographical regions. Only two type 027 isolates were found, both from the same patient. In the second study, involving all 28 regional laboratories, all consecutive C. difficile isolates collected during two time periods in 2009 (n=364) were typed and tested for susceptibility to clindamycin, erythromycin, moxifloxacin, metronidazole and vancomycin. The three most common PCR ribotypes were SE21, 001 and 020 (22% of all isolates). Types 012, 017, and 046 were geographically clustered and associated with decreased susceptibility to moxifloxacin, clindamycin and erythromcin. The extent of moxifloxacin prescription was highly variable among counties, indicating a need for careful monitoring of prescription rates to follow its role in C. difficile epidemiology.</abstract><cop>Sweden</cop><pub>Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)</pub><pmid>21435322</pmid><doi>10.2807/ese.16.10.19813-en</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1560-7917
ispartof Euro surveillance : bulletin européen sur les maladies transmissibles, 2011-03, Vol.16 (10), p.18
issn 1560-7917
1025-496X
1560-7917
language eng
recordid cdi_proquest_miscellaneous_865693630
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Anti-Bacterial Agents - pharmacology
Aza Compounds - pharmacology
Bacteria
Clostridium difficile - classification
Clostridium difficile - drug effects
Clostridium difficile - genetics
Clostridium difficile - isolation & purification
Cluster Analysis
DNA Gyrase - genetics
Drug resistance
Drug Resistance, Bacterial
Enterocolitis, Pseudomembranous - epidemiology
Enterocolitis, Pseudomembranous - microbiology
Epidemiology
Fluoroquinolones
Geography
Humans
Infectious diseases
Laboratories
Microbial Sensitivity Tests
Molecular Epidemiology
Moxifloxacin
Polymerase Chain Reaction
Population Surveillance
Prescription drugs
Prevalence
Quinolines - pharmacology
Ribotyping
Surveillance
Sweden - epidemiology
title Geographical clustering of cases of infection with moxifloxacin-resistant Clostridium difficile PCR-ribotypes 012, 017 and 046 in Sweden, 2008 and 2009
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T20%3A15%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Geographical%20clustering%20of%20cases%20of%20infection%20with%20moxifloxacin-resistant%20Clostridium%20difficile%20PCR-ribotypes%20012,%20017%20and%20046%20in%20Sweden,%202008%20and%202009&rft.jtitle=Euro%20surveillance%20:%20bulletin%20europ%C3%A9en%20sur%20les%20maladies%20transmissibles&rft.au=Akerlund,%20T&rft.aucorp=Swedish%20C.%20difficile%20Study%20Group&rft.date=2011-03-10&rft.volume=16&rft.issue=10&rft.spage=18&rft.pages=18-&rft.issn=1560-7917&rft.eissn=1560-7917&rft_id=info:doi/10.2807/ese.16.10.19813-en&rft_dat=%3Cproquest_cross%3E865693630%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=857841250&rft_id=info:pmid/21435322&rfr_iscdi=true